Galectin Therapeutics Inc. (GALT)

[jimmy667]

Need bona fide investing experience and a liquid net worth of over a million US Dollars. Means need stocks bonds and cash in bank of over a million but they may have raised that amount.
It looks to me like short sellers will attack this stock now that they have given up trying to sell this company and three years until read out on the phase 3.

[buckysherm]

How does one get to be “accredited” ?

[buckysherm]

The 52 Week High is shown as 499 Million ! I must have missed that day.

[thefamilyman]

LOL! And thanks for both responses.

[jimmy667]

If you are retail in this stock you are just along for the ride. Every non revenue biotech must dilute to stay afloat. Most dilute all equally. GALT will dilute mostly those that can not subscribe to the new stock subscription program. The Chairman will buy 20 million in stock and warrants with a 5 strike. Only current investors that are also certified accredited investors may do the same. Other current shareholders will be diluted. Also puts a resistance level in above $5 as warrants can be exercised at that price. Positives are much needed cash is coming and the stock is going into strong hands and it is less dilution than another type of cash raise. Also makes a takeover buy new entity more expensive. Negatives it dilutes the common shareholders who can not subscribe to the stock/warrants purchase plan nor can new investors who might be dissuaded by entering at this time just to be immediately diluted. This stock may continue to correct downward as a result of this in the short term but in the long term will be favorable as the Company will now have cash to move forward with the very promising clinical trials. Looks like the sell the Company before the end of 2018 was not fruitful. Maybe because potential suitors were playing hardball because Gallactin was cash strapped.
I urge everyone to read Uihien's March 6 open letter to shareholders.
Long term good news with some temporary pain to common stock holders.
I might look to enter in a quarter or two when the warrants do not present as much of a cap on the share price and trials are underway in earnest.

[jimmy667]

Ok funnyman it is not an app it is a stock subscription plan for stockholders of record as of the initiation date that are also certified as accredited investors. For the big boys insiders and tutes. It is in the SEC filings if you care to read about it.

[thefamilyman]

How do I access the app?

[jimmy667]

They turned on the financing app with the shareholder subscription stock sell package. Uhline is buying the first $20 million. Only current shareholders can participate but one must be an accredited investor as defined by the SEC. I am but I am not a current shareholder. Unfortunately this leaves 90% or better of current retail locked out. But it does provide financing that is less dilution to the big boys but us small fries or non shareholders can not participate so I will wait until it is fully subscribed to buy in.

[buckysherm]

Hello ? < tap tap > Is this thing on ?

[Amatuer17]

The lack of cash and mgmt failure to show move faster leads market to show no confidence

[Chess Master]

GALT is the last man standing in this space. The Press release seems to have fallen on deaf ears due to the market selloff.

[buckysherm]

Is WS and BP smart enough to act on it ? I doubt it

[Amatuer17]

GILD failed - CNAT failed

Who is remaining now in NASH space?

GALT has P3 ready NASH product
Also GLAT is only NASH-CX ready product to start Phase 3 trial and completed FDA meeting for trial readiness.

If BP gives just $10-20 million for the trial they can have a good lock on future NASH product. Even a failure may not impact BP as they are eliminating P1-P2 timeline and money.

[whytestocks]

News: $GALT Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology

NORCROSS, Ga., March 22, 2019 (GLOBE NEWSWIRE) -- Providence Cancer Institute and Galectin Therapeutics Inc. (NASDAQ: GALT) , the leading developer of therapeutics that target galectin proteins, announced today a presentation highlighting the improved response of T cells seen in combinatio...

In case you are interested https://marketwirenews.com/news-releases/providence-cancer-institute-to-present-findings-on-gr-md-02-at-the-2019-keystone-symposia-on-molecular-and-cellular-biology-7864016.html

[1234jklm]

Huge news. The team that helped win the 2018 Nobel prize for cancer immunotherapy, and conducting the cancer IO trial in humans is now saying, in an upcoming conference, that GR-MD-02 improves overall cancer survival: "Galectin-3 Inhibition with GR-MD-02 Synergizes with T Cell-Targeting Immunotherapy, Leading to Reduced Immune Suppression and Improved Overall Survival."

This is very significant because researchers are traditionally extremely cautious about making any claims about a cancer drug improving overall survival unless the data is rock solid. Providence has new data coming up. Patients who respond to GR-MD-02 have the option to continue therapy, and apparently the results are very good!

http://www.keystonesymposia.org/index.cfm?e=Web.Meeting.Program&meetingid=1626&subTab=program

[stock_observer_77]

Sounds like you've been here too long

Things change...I'm fine here

[buckysherm]

Sure it’s necessary, but it’s a disappointment that GALT can’t find a partner for NASH .... or Cancer ....

[stock_observer_77]

You have to consider if its adding value

Let's be real here...adding dilution for nothing is bad...adding for value is a wash.

[superdodgeball]

FAKE NEWS... there's no Russian Dilutions going on here. haha.

[buckysherm]

Dilution isn’t really the relevant thing. It’s INFLATION of shares. Like when govt “prints” more money, each individual $ is worth less.

[Phantom Lord]

If every current owner purchases their pro rata allotment of shares and that is all that happens then technically there is no dilution. Dilution has nothing to do with market cap or share price. Just ownership. They are not issuing shares to new investors, just current ones. If you don't purchase shares in the offering then yes, you will suffer some dilution. If you do purchase your pro rata allotment of shares in the offering then you have not been diluted. It's that simple.

[biotech2010]

Of course there is dilution, they are issuing new shares so unless the market cap increases the value per share will go down regardless of whether you bought additional shares or not.

[Phantom Lord]

But the offering is only available to existing shareholders. So if everyone purchases their pro rata allotment of shares then technically there is no dilution. That's the point they are failing to make. It's definitely dilution if you don't purchase more shares in the offering. That the way I read it.

[buckysherm]

In Stock Twits they are trying to spin this into THERES NO DILUTION ?!?? They’re gonna increase shares ... your existing shares are gonna be less valuable. Duh !

[thefamilyman]

I like that letter to the shareholders and I intend to subscribe for my full allocation of shares and warrants.

[biotech2010]

Yes I was, not a surprise at all

[buckysherm]

Think about how many effing possible indication GRMD02 could be used for. And every cancer. And NASH. No BP is effing interested ? I thought they were stupid, but not THIS stupid !

[goingforittoday]

Chairman adds $20M, and x10, all, are fully converted to common? That’s quite a statement of confidence!! Kudos!

[stock_observer_77]

Looks like you are correct!

[sokol]

Richard E. Uihlein maintains that he intends to invest more of his personal funds and invites investors to do so along with him. He says he intends to subscribe to $20,000,000 of a new offering to move the company forward. If so, I suppose that should be somewhat of a positive indication although $20,000,000 for him may not be that large of a percentage of his networth? I have not had time to study this to make a firm decision about whether I desire to invest more to account for the dilution in ownership that this may otherwise cause? However, that is what he invites existing investors to do.

[stock_observer_77]

That makes no sense, but to each his own

[biotech2010]

They've been actively looking for a partnership.buyout since last May and have not announced anything to suggest they've found one, that's enough for me to form an opinion about partnerships or a buyout

[stock_observer_77]

How do you know they struck out

[biotech2010]

Anyone who pays attention to the continual pumping of GALT on Stocktwits is asking for trouble-GALT has great science but poorly managed and would have to hire a whole new team to run a Ph3 trial and will most likely have to internally finance a phase 3, they have struck out on a buyout or partner, IMO

[goingforittoday]

Gilead's Recent NASH Trial Failure Represents Opportunity For Galectin https://seekingalpha.com/article/4242202?source=ansh $GALT, $GILD

[buckysherm]

Today’s SA article may bump it up a couple percent today.

[Amatuer17]

Good article

Gilead's Mousetrap $GILD https://seekingalpha.com/article/4241397

[Amatuer17]

Don’t be so sure. This move is based on GILD CX trial failure.

The co has no progress or no positive news. They cannot even start trial unless they get a partner and then funding.

So unless there is actual news on partnership or BO the SP will go down.

[stock_observer_77]

$5 break is imminent leading to higher highs

[heartofachild]

Thanks for this, I've been watching and holding

[goingforittoday]

Price target $11
https://www.google.com/amp/s/www.smarteranalyst.com/brief/b-riley-fbr-initiates-a-buy-rating-on-galectin-therapeutics-galt/amp/

[stock_observer_77]

Oh sorry you mean drop in short interest

I agree with that

[mikeslife]

Short interest dropped almost 525,000 shares (12.7%) in the first 2 weeks of January. Still 3,603,000 short interest but looking for a more dramatic downturn over the next month.

[Amatuer17]

This is good article and the comment section has some good discussions

[stock_observer_77]

Thanks

[goingforittoday]

Good read
Update On NASH Antifibrotics:Allergan Gilead Conatus Galectin
Update On NASH Antifibrotics: Allergan, Gilead, Conatus, Galectin https://seekingalpha.com/article/4235433?source=ansh $CNAT, $AGN, $GALT, $GILD

[stock_observer_77]

True

But the PR was the key

[buckysherm]

But pretty much like last years ... as far as I can tell.

[stock_observer_77]

Looks like they got options

The puzzle is forming. Pieces are being put in place.

[buckysherm]

What’s with all the Form 4’s ? Did execs just get options or are they exercising them ?